{
    "id": "atlas_score",
    "title": "ATLAS Score for Clostridium Difficile Infection",
    "description": "Predicts response to therapy in C. diff patients",
    "category": "infectious_disease",
    "subcategory": "bacterial_infections",
    "abbreviation": "ATLAS",
    "version": "1.0",
    "references": [
        {
            "citation": "Miller MA, Louie T, Mullane K, Weiss K, Lentnek A, Golan Y, et al. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to vancomycin therapy. BMC Infect Dis. 2013;13:148.",
            "url": "https://pubmed.ncbi.nlm.nih.gov/23547790/",
            "pmid": "23547790"
        },
        {
            "citation": "Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431-55.",
            "url": "https://pubmed.ncbi.nlm.nih.gov/20307191/",
            "pmid": "20307191"
        }
    ],
    "formula": "Sum of points from: Age ≥65 (+1), Treatment with Systemic Antibiotics (+2), Leukocytosis >15,000/μL (+1), Albumin <2.5 g/dL (+1), Serum Creatinine >1.5× baseline (+1)",
    "parameters": [
        {
            "name": "age_65_or_older",
            "label": "Age ≥65 years",
            "type": "boolean",
            "required": true,
            "points": {
                "true": 1,
                "false": 0
            },
            "description": "Patient is 65 years of age or older"
        },
        {
            "name": "systemic_antibiotics",
            "label": "Treatment with Systemic Antibiotics",
            "type": "boolean",
            "required": true,
            "points": {
                "true": 2,
                "false": 0
            },
            "description": "Patient is currently on systemic antibiotic therapy (other than for C. diff treatment)"
        },
        {
            "name": "leukocytosis",
            "label": "Leukocytosis >15,000/μL",
            "type": "boolean",
            "required": true,
            "points": {
                "true": 1,
                "false": 0
            },
            "description": "White blood cell count greater than 15,000 cells per microliter"
        },
        {
            "name": "low_albumin",
            "label": "Albumin <2.5 g/dL",
            "type": "boolean",
            "required": true,
            "points": {
                "true": 1,
                "false": 0
            },
            "description": "Serum albumin level less than 2.5 g/dL (25 g/L)"
        },
        {
            "name": "elevated_creatinine",
            "label": "Serum Creatinine >1.5× baseline",
            "type": "boolean",
            "required": true,
            "points": {
                "true": 1,
                "false": 0
            },
            "description": "Serum creatinine level greater than 1.5 times the baseline/normal value"
        }
    ],
    "result": {
        "name": "atlas_score",
        "type": "integer",
        "unit": "points",
        "description": "ATLAS score for predicting response to C. difficile therapy"
    },
    "interpretation": {
        "ranges": [
            {
                "min": 0,
                "max": 2,
                "label": "Low Risk",
                "color": "green",
                "description": "Good response to vancomycin therapy expected. Low risk of treatment failure.",
                "management": "Standard vancomycin therapy should be effective. Monitor clinical response."
            },
            {
                "min": 3,
                "max": 6,
                "label": "High Risk",
                "color": "red",
                "description": "Poor response to vancomycin therapy expected. High risk of treatment failure.",
                "management": "Consider alternative therapies such as fidaxomicin or fecal microbiota transplantation. Close monitoring required."
            }
        ]
    },
    "clinical_use": {
        "indications": [
            "Patients with confirmed Clostridium difficile infection",
            "Treatment planning for C. diff infection",
            "Predicting response to vancomycin therapy",
            "Risk stratification for treatment failure"
        ],
        "contraindications": [
            "Not validated for pediatric patients",
            "Should not be used in isolation for treatment decisions"
        ],
        "limitations": [
            "Derived from patients treated with vancomycin specifically",
            "May not apply to other C. diff treatments",
            "External validation in diverse populations needed"
        ]
    },
    "evidence_summary": "The ATLAS score was derived and validated in a multicenter study to predict response to vancomycin therapy in C. difficile infection. It identifies patients at high risk for treatment failure who may benefit from alternative therapeutic approaches.",
    "author": "Dr. Mark Miller",
    "created_date": "2013-03-26",
    "last_updated": "2024-01-15",
    "medical_specialty": "Infectious Disease",
    "tags": [
        "c-diff",
        "cdiff",
        "clostridium difficile",
        "antibiotic therapy",
        "treatment response",
        "vancomycin",
        "infectious disease",
        "gastrointestinal infection"
    ]
}
